Finding a way to slow cognitive decline in Alzheimer's disease using a new treatment approach.
Development of a RUNX1 modulator to slow cognitive decline in Alzheimer's disease
This study is looking at a new treatment that could help improve brain function and slow down memory loss in people with Alzheimer's by targeting a specific factor in the brain, and they're testing it in mice to see if it works.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Third Element Bio INC. NIH-funded |
| Lab location | 1 site (San Diego, United States) |
| Project ID | NIH-11067457 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment that targets a specific factor called RUNX1, which is believed to contribute to cognitive decline in Alzheimer's disease (AD). The researchers aim to create a type of medication that can lower RUNX1 levels in brain cells, potentially improving brain function and slowing down the progression of AD. They will test this treatment in mouse models to see if it can effectively enhance cognitive abilities and reduce symptoms associated with Alzheimer's. If successful, this approach could lead to safer and more effective therapies for patients suffering from AD.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of Alzheimer's disease.
Not a fit: Patients under the age of 65 or those without cognitive impairment related to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel treatment option that slows cognitive decline in Alzheimer's patients.
How similar studies have performed: While targeting RUNX1 is a novel approach, similar strategies targeting microglial function have shown promise in other studies.
Where this research is happening
San Diego, United States
- Third Element Bio INC. — San Diego, United States (Active)
Researchers
- Principal investigator: Palmer, Carter Rodman — Third Element Bio INC.
- Study coordinator: Palmer, Carter Rodman
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.